Aug 13, 2015 4:05 pm EDT Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights
Aug 06, 2015 8:00 am EDT Capricor Therapeutics to Hold Second Quarter 2015 Business Update and Financial Results Conference Call on August 13, 2015 at 4:30 p.m. EDT
Aug 04, 2015 8:00 am EDT Capricor Therapeutics Appoints Deborah Ascheim, M.D. as Chief Medical Officer
Jun 17, 2015 8:00 am EDT Capricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. to Vice President of Medical and Clinical Development for New Therapies
Jun 15, 2015 8:00 am EDT Capricor Therapeutics and CureDuchenne to Host Webinar on June 19, 2015 at 3:00 p.m. ET
Jun 08, 2015 8:42 am EDT Capricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy
May 26, 2015 4:15 pm EDT Capricor Therapeutics to Participate in Two Upcoming Investor Conferences in June
May 12, 2015 4:01 pm EDT Capricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights
May 05, 2015 4:05 pm EDT Capricor Therapeutics to Hold First Quarter 2015 Business Update and Financial Results Conference Call on May 12, 2015 at 4:30 p.m. EDT
Apr 22, 2015 8:00 am EDT Capricor Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy